blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2444082

EP2444082 - Hydroxymethylbutyrate compositions and uses thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.07.2019
Database last updated on 03.08.2024
FormerThe patent has been granted
Status updated on  10.08.2018
FormerGrant of patent is intended
Status updated on  25.03.2018
Most recent event   Tooltip09.07.2021Lapse of the patent in a contracting state
New state(s): HU		published on 11.08.2021  [2021/32]
Applicant(s)For all designated states
ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park, IL 60064-3500 / US
[2018/37]
Former [2012/17]For all designated states
Abbott Laboratories
D-377/AP6A-1 100 Abbott Park Road
Abbott Park, Illinois 60064-6008 / US
Inventor(s)01 / Baxter, Jeffrey, H
711 Caroway Blvd.
Gahanna, Ohio 43230 / US
02 / Mukerji, Pradip
1069 Arcaro Drive
Gahanna, Ohio 43230 / US
03 / Voss, Anne, C
1526 Bridgeton Drive
Columbus, Ohio 43220 / US
04 / Tisdale, Michael J
Aston University, Aston Triangle
Birmingham, B4 7ET / GB
 [2018/17]
Former [2012/17]01 / Baxter, Jeffrey, H
711 Caroway Blvd.
Gahanna, OH Ohio 43230 / US
02 / Mukerji, Pradip
1069 Arcaro Drive
Gahanna, OH Ohio 43230 / US
03 / Voss, Anne, C
1526 Bridgeton Drive
Columbus, OH Ohio 43220 / US
04 / Tisdale, Michael J
Aston University, Aston Triangle
Birmingham, B4 7ET / GB
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[N/P]
Former [2018/37]Boult Wade Tennant LLP
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Former [2013/12]Ricker, Mathias, et al
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte
Zweibrückenstraße 5-7
80331 München / DE
Former [2012/17]Modiano, Micaela Nadia, et al
Modiano & Partners (DE)
Thierschstrasse 11
80538 München / DE
Application number, filing date11187274.314.03.2005
[2012/17]
Priority number, dateUS2004081076226.03.2004         Original published format: US 810762
[2012/17]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2444082
Date:25.04.2012
Language:EN
[2012/17]
Type: A3 Search report 
No.:EP2444082
Date:01.08.2012
Language:EN
[2012/31]
Type: B1 Patent specification 
No.:EP2444082
Date:12.09.2018
Language:EN
[2018/37]
Search report(s)(Supplementary) European search report - dispatched on:EP28.06.2012
ClassificationIPC:A61K31/19, A61K31/205, A61K31/202, A61K31/702, A61P35/00, A61P31/00, A61P3/02, A61P19/02, A61P1/16, A61P1/12, A61P13/12, A61P11/00
[2012/17]
CPC:
A61K31/19 (EP,KR,US); A61K31/205 (KR); A61P1/00 (EP);
A61P1/04 (EP); A61P1/12 (EP); A61P1/16 (EP);
A61P11/00 (EP); A61P13/12 (EP); A61P17/02 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P25/18 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/02 (EP);
A61P3/04 (EP); A61P3/12 (EP); A61P31/00 (EP);
A61P31/18 (EP); A61P35/00 (EP); A61P37/00 (EP) (-)
C-Set:
A61K31/19, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/37]
Former [2012/17]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Hydroxymethylbutyratzusammensetzungen und deren Verwendungen[2012/17]
English:Hydroxymethylbutyrate compositions and uses thereof[2012/17]
French:Compositions d'hydroxyméthylbutyrate et leurs utilisations[2012/17]
Examination procedure15.01.2013Examination requested  [2013/09]
14.03.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
24.05.2013Amendment by applicant (claims and/or description)
13.03.2014Despatch of a communication from the examining division (Time limit: M04)
23.07.2014Reply to a communication from the examining division
08.01.2016Despatch of a communication from the examining division (Time limit: M04)
17.03.2016Reply to a communication from the examining division
26.03.2018Communication of intention to grant the patent
01.08.2018Fee for grant paid
01.08.2018Fee for publishing/printing paid
01.08.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP05732120.0  / EP1727534
EP10186645.7  / EP2301529
Opposition(s)13.06.2019No opposition filed within time limit [2019/34]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
24.05.2013Request for further processing filed
24.05.2013Full payment received (date of receipt of payment)
Request granted
17.06.2013Decision despatched
Fees paidRenewal fee
31.10.2011Renewal fee patent year 03
31.10.2011Renewal fee patent year 04
31.10.2011Renewal fee patent year 05
31.10.2011Renewal fee patent year 06
31.10.2011Renewal fee patent year 07
07.03.2012Renewal fee patent year 08
08.03.2013Renewal fee patent year 09
10.03.2014Renewal fee patent year 10
06.03.2015Renewal fee patent year 11
08.03.2016Renewal fee patent year 12
07.03.2017Renewal fee patent year 13
08.03.2018Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2005
AT12.09.2018
CY12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
TR12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
IE14.03.2019
LU14.03.2019
BE31.03.2019
CH31.03.2019
FR31.03.2019
LI31.03.2019
[2021/32]
Former [2021/26]AT12.09.2018
CY12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
TR12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
IE14.03.2019
LU14.03.2019
BE31.03.2019
CH31.03.2019
FR31.03.2019
LI31.03.2019
Former [2020/17]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
TR12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
IE14.03.2019
LU14.03.2019
BE31.03.2019
CH31.03.2019
FR31.03.2019
LI31.03.2019
Former [2020/11]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
IE14.03.2019
LU14.03.2019
BE31.03.2019
CH31.03.2019
FR31.03.2019
LI31.03.2019
Former [2020/09]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
IE14.03.2019
LU14.03.2019
Former [2020/01]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
LU14.03.2019
Former [2019/46]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
MC12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
Former [2019/37]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SI12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
Former [2019/34]AT12.09.2018
CZ12.09.2018
DK12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
Former [2019/26]AT12.09.2018
CZ12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
PT12.01.2019
Former [2019/23]AT12.09.2018
CZ12.09.2018
EE12.09.2018
FI12.09.2018
LT12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
SK12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
Former [2019/22]CZ12.09.2018
FI12.09.2018
LT12.09.2018
NL12.09.2018
PL12.09.2018
RO12.09.2018
SE12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
Former [2019/21]FI12.09.2018
LT12.09.2018
NL12.09.2018
SE12.09.2018
BG12.12.2018
GR13.12.2018
IS12.01.2019
Former [2019/20]FI12.09.2018
LT12.09.2018
NL12.09.2018
SE12.09.2018
BG12.12.2018
GR13.12.2018
Former [2019/10]FI12.09.2018
LT12.09.2018
SE12.09.2018
BG12.12.2018
GR13.12.2018
Former [2019/08]FI12.09.2018
LT12.09.2018
Former [2019/07]LT12.09.2018
Documents cited:Search[X]WO9414429  (UNIV IOWA STATE RES FOUND INC [US], et al) [X] 1-4 * abstract * * page 2, paragraph 2 *;
 [XD]DE29707308U  (KUNZ ARMIN [DE]) [XD] 1-4 * the whole document *;
 [X]WO9804253  (BEALE PAXTON K [US]) [X] 1-4 * abstract * * page 9, lines 12-14 * * page 10, lines 12-19 * * page 14, lines 6-18; claims 1,12,15 *;
 [X]WO9966917  (UNIV IOWA STATE RES FOUND INC [US], et al) [X] 1-4 * abstract * * page 17, lines 3-10; claim 28 * * page 3, line 29 - page 6, line 10 * * page 8, line 7 - page 9, line 18 *;
 [X]WO0217735  (LONZA AG [CH], et al) [X] 5,6,11-13,15,16 * abstract * * page 8, paragraph 3 - page 11, paragraph 4 *;
 [XY]  - MAY PATRICIA EUBANKS ET AL, "Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine.", AMERICAN JOURNAL OF SURGERY. APR 2002, (200204), vol. 183, no. 4, ISSN 0002-9610, pages 471 - 479, XP008063769 [X] 1-4 * the whole document * [Y] 1-4

DOI:   http://dx.doi.org/10.1016/S0002-9610(02)00823-1
 [X]  - CLARK R H ET AL, "Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study.", JPEN. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION. 2000 MAY-JUN, (200005), vol. 24, no. 3, ISSN 0148-6071, pages 133 - 139, XP009004307 [X] 1-4 * the whole document *
 [XP]  - RATHMACHER, J. A. ET AL, "Supplementation with a combination of .beta.-hydroxy-.beta.-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters", JPEN, JOURNAL OF PARENTERAL AND ENTERAL NUTRITION , 28(2), 65-75 CODEN: JPENDU; ISSN: 0148-6071, (2004), XP008063815 [XP] 1-4 * abstract *
 [XP]  - SMITH HELEN J ET AL, "Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.", CANCER RESEARCH. 1 DEC 2004, (20041201), vol. 64, no. 23, ISSN 0008-5472, pages 8731 - 8735, XP008063768 [XP] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-04-1760
 [Y]  - ZUIJDGEEST-VAN LEEUWEN S D ET AL, "O.44 Inhibition of lipolysis by eicosapentaenoic acid in weight-losing cancer patients and healthy volunteers", CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, (19980801), vol. 17, doi:10.1016/S0261-5614(98)80112-X, ISSN 0261-5614, page 13, XP004683916 [Y] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0261-5614(98)80112-X
 [Y]  - KRITCHEVSKY D, "An international symposium on cancer cachexia, cytokines, and EPA: Introduction", NUTRITION, ELSEVIER INC, US, (19960101), vol. 12, no. 1, doi:10.1016/0899-9007(95)00076-3, ISSN 0899-9007, page S1, XP004703860 [Y] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1016/0899-9007(95)00076-3
 [Y]  - TISDALE M J, "Inhibition of lipolysis and muscle protein degradation by epa in cancer cachexia", NUTRITION, ELSEVIER INC, US, (19960101), vol. 12, no. 1, doi:10.1016/0899-9007(95)00066-6, ISSN 0899-9007, pages S31 - S33, XP004703868 [Y] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1016/0899-9007(95)00066-6
 [X]  - ALON TAL ET AL, "Supplementing with beta-hydroxy-beta-methylbutyrate (HMB) to build and maintain muscle mass: a review.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (2002), Database accession no. NLM14632320, XP002677619 [X] 1-4 * abstract *
    [ ] - ALON TAL ET AL, "Supplementing with beta-hydroxy-beta-methylbutyrate (HMB) to build and maintain muscle mass: a review.", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY 2002 LNKD- PUBMED:14632320, (2002), vol. 111, no. 1-4, ISSN 1078-0297, pages 139 - 151
 [X]  - DE LOS REYES ALEXANDER D ET AL, "Overview of resistance training, diet, hormone replacement and nutritional supplements on age-related sarcopenia--a minireview.", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY 2003 LNKD- PUBMED:15686115, (2003), vol. 113-114, ISSN 1078-0297, pages 159 - 170, XP002677620 [X] 1-4 * abstract * * page 166, paragraph 3 - page 168, paragraph 1 *
 [X]  - VUKOVICH M D ET AL, "Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults.", THE JOURNAL OF NUTRITION JUL 2001 LNKD- PUBMED:11435528, (200107), vol. 131, no. 7, ISSN 0022-3166, pages 2049 - 2052, XP002677621 [X] 1-4 * the whole document *
 [XP]  - FLAKOLL PAUL ET AL, "Effect of . beta .- hydroxy -. beta .- methylbutyrate , arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women", NUTRITION, ELSEVIER INC, US, vol. 20, no. 5, doi:10.1016/J.NUT.2004.01.009, ISSN 0899-9007, (20040501), pages 445 - 451, (20040426), XP008152353 [XP] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.nut.2004.01.009
by applicantUS4871760
 US4992470
 US5028440
 US5085883
 US5223285
 US5348979
 US5444054
 US5457130
 DE29707308U
 US5780451
 US5792502
 US5976550
 US6031000
 US6160007
 US6176980
 US6194379
    - WITTE, K, K. A., CLARK, A. L., "Nutritional abnormalities contributing to cachexia In chronic illness", INTERNATIONAL JOURNAL OF CARDIOLOGY, (2002), vol. 85, pages 23 - 31
    - KUFSUZAWA, T ET AL., "Muscle energy metabolism and nutritional status in patients with chronic obstructive pulmonary disease", AM. J. RESPIR, CRIT, CARE MED., (1995), vol. 152, no. 2, pages 647 - 662
    - SCHOLS, A. M. ET AL., "Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators In a subgroup of patients with chronic obstructive pulmonary disease", THORAX, (1996), vol. 61, pages 819 - 824, XP009085867
    - TAKABATAKE, N ET AL., "Circulating loptin In patients with chronic obstructive pulmonary disease", AM J RESPLR CRLT CARE MED, (1999), vol. 159, pages 1215 - 1219
    - DENTENER, M, A. ET AL., "Systemic anti-inflammatory mediators In COPD: Increase In soluble Interleukin I receptor II during treatment of exacerbations", THORAX, (2001), vol. 56, doi:doi:10.1136/thorax.56.9.721, pages 721 - 726, XP009085668

DOI:   http://dx.doi.org/10.1136/thorax.56.9.721
    - SCHOLS, A. M. W. J., "Pulmonary cachexta", INTL J CARDIOLOGY, (2002), vol. 85, pages 101 - 110
    - JAGOE, R, T., GOLDBERG, A. L., "What do we really know about the ubiquitin-proteosome pathway In muscle atrophy?", CURR OPLN CLIN NUTR METAB CARE, (2001), vol. 4, pages 183 - 190
    - BARBER, M.D., ROSS, J.A., VOSS, A,C., TISDALE, M.J., FEARON, K.C,H., "The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer", BR. J. CANCER, (1999), vol. 81, pages 80 - 86
    - MAY, P.E., BARBER, A, D'OLLMPIO, J.T., HOURTHANE, A., ABUMRAD, N,N, "Reversal of cancer-related wasting using oral supplementation with a combination of ?-hydroxy-?-methylbutyrate, arginine and glutamine", AM. J. SURG., (2002), vol. 183, doi:doi:10.1016/S0002-9610(02)00823-1, pages 471 - 479, XP008063769

DOI:   http://dx.doi.org/10.1016/S0002-9610(02)00823-1
    - TISDALE ET AL., CANCER RESEARCH, (199008), vol. 50, pages 5022 - 5026
    - BRENNAN, M.F., BURT, M.E., CANCER TREATMENT REPORTS, (1981), vol. 65, no. 5, pages 67 - 68
    - KISNER, D.L., CANCER TREATMENT REPORTS, (1981), vol. 65, no. 5, pages 1 - 2
    - CA CARTER, "Protein kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer", CURRENT DRUG TARGETS, (2000), vol. 1, doi:doi:10.2174/1389450003349317, pages 163 - 183, XP002669613

DOI:   http://dx.doi.org/10.2174/1389450003349317
    - P. G. GOEKJIAN, M. R. JIROUSEK, "Proteln Kinase C in the Treatment of Disease; SIgnal Transduction Pathways, Inhibitors, and Agents in Development", CURRENT MEDICINAL CHEMISTRY, (1999), vol. 6, no. 9, pages 877 - 903, XP001009989
    - "The tumor promoter receptor protein kinase C: A novel target for chemopreventlon and therapy of human colon cancer", CA IO'BRIAN, NE WARD, KGRAVIT, I

    - F BATTAINL, "Protein kinase C isoforms as therapeutic targets in nervous system disease slates", PHARMACOLOGICAL RESEARCH, (2001), vol. 44, no. 5, pages 353 - 361
    - RN FRANK, "Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors", AM J OPHTHALMOL, (2002), vol. 133, doi:doi:10.1016/S0002-9394(02)01321-1, pages 693 - 698, XP002669612

DOI:   http://dx.doi.org/10.1016/S0002-9394(02)01321-1
    - M MEIER, GL KING, "Protein kinase C activation and Its pharmacological Inhibition in vascular disease", VASCULAR MEDICINE, (2000), vol. 5, pages 173 - 185
    - AB LENTSCH, PA WARD, "Activation and regulation of NFKB during acute inflammation", CLIN CHEM LAB MED, (1999), vol. 37, no. 3, pages 205 - 208
    - VB ANDELA, AH GORDON, G ZOTALLS, RN ROSIER, JJ GOATER, GD LEWIS, EM SCHWARZ, JE PUZAS, RJ O'KEEFE, "NFKB: A pivotal transcription factor in prostate cancer metastasis to bone", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, (2003), vol. 416S, doi:doi:10.1097/01.blo.0000093048.96273.aa, pages S75 - S85, XP009116083

DOI:   http://dx.doi.org/10.1097/01.blo.0000093048.96273.aa
    - E. HO, TM BRAY, "Antfoxldants, NF?B activation and diabetogenesis", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1999), vol. 222, pages 205 - 213
    - J MOSCAT, MT DIAZ· MECO, P RENNERT, "NFKB activation by proplein kinase C lsoformsand ?-cell function", EMBO REPORTS, (2003), vol. 4, pages 31 - 36
    - F. DELFINO, WH WALKER, "Hormonal regulation of the NFKB signaling pathway", MOLECULAR AND CELLULAR ENDOCRINOLOGY, (1999), vol. 167, pages 1 - 9
    - TM WATOHORN, I WADDELL, N DOWLDAR, JA ROSS, "Proteolysis-Inducing factor regulates hepatic gene expression via the transoription factor NFKB and STST3", FASEB J, (2001), vol. 15, pages 562 - 564
    - COFFMAN ET AL., J. AM. CHEM. SOC., (1968), vol. 80, pages 2882 - 2887
    - INFORM, (199710), vol. 8, no. 10, page 1004
    - BIBBY, M.C. ET AL., "Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals", J. NATL. CANCER INST., (1987), vol. 78, pages 539 - 546
    - WAALKES, T.P. ET AL., "A fluorimetric method for the estimation of tyrosine In plasma and tissues", J. LAB. CLIN. MED., (1957), vol. 50, pages 733 - 736
    - ORINO, E. ET AL., "ATP-dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubitquitinated proteins in human HL-60 celfs", FEBS LETT., (1991), vol. 284, pages 206 - 210
    - TODOROV, P. ET AL., "Characterization of a cancer cachectic factor", NATURE, (1996), vol. 379, doi:doi:10.1038/379739a0, pages 739 - 742, XP002927496

DOI:   http://dx.doi.org/10.1038/379739a0
    - TODOROV, P, "lnduction of muscle protein degradation and weight loss by a tumor product", CANCER RES., (1996), vol. 56, pages 1256 - 1261, XP002474064
    - SMITH, H ET AL., "Effect of a cancer cachectic factor on protein synthesis I degradation In murine C2C12 myoblasts: Modulation by elcosapentaenoic acid", CANCER RES., (1999), vol. 59, pages 5507 - 5513
    - ORINO, E, "ATP-dependent reversible association of proteasomes with multiple protein components to form 268 complexes that degrade ubiqultinatedproteins in human Hl-60 cells", FEBS LETT., (1991), vol. 284, pages 206 - 210
    - WHITEHOUSE, A.S. ET AL., "Increased expression of the ubiqullin-proteasome pathway In murine myotubes by proteolysis-inducing factor (PIF) Is associated with activation of the transcription factor NF-?B", BR. J. CANCER, (2003), vol. 89, pages 1116 - 1122
    - FENTEANY, G. ET AL., "Lactacystin, proteasome function and cell fate", J. BIOL. CHEM., (1998), vol. 273, pages 8545 - 8548
    - ANDREWS, N.C. ET AL., "A rapid micropreparatlon technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells", NUCLEIC ACIDS RES., (1991), vol. 19, page 2499
    - GOMES-MARCONDES ET AL., "Development of an in- vitro model system to Investigate the mechanism of muscle protein catabolism Induced by proteolysls-inducing factor", BR. J. CANCER, (2002), vol. 86, pages 1628 - 1633
    - SMITH, H.J. ET AL., "Effect of a cancer cachectic factor on protein synthesis / degradation In murine C2C12 myobiasis; Modulation by elcosapentaenoic acid", CANCER RES, (1999), vol. 59, pages 5507 - 5513
    - WHITEHOUSE, A.S. ET AL., "induction of protein catabolism In myotubes by 16(S)-hydroxyelcosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway", BR. J. CANCER, (2003), vol. 89, pages 737 - 745
    - WHITEHOUSE, A.S. ET AL., "Increased expression of the ubiquitin-proteasome pathway in murine myotubes by protealysis-inducing factor (PIF) is associated with activation of the transcription factor NF-?B", BR. J. CANCER, (2003), vol. 89, pages 1116 - 1122
    - LORITE,M.J., SMITH, H.J., ARNOLD, J.A., MORRIS, A., THOMPSON, M.G., TISDALE, M. J., "Activation of ATP-ubiqultin-dependent proteolysis In skeletal muscle In vivo and murinemyoblastsin vitro by a proteolysis-inducing factor (PlF", BR. J. CANCER, (2001), vol. 85, pages 297 - 302
    - GOMES-MARCONDES, M,C,C., SMITH, H.J., COOPER, J.C., TISDALE, M.J., "Development of an ln-vitro model system to Investigate the machanism of muscle protein catabolism induced by proteolysis-inducing factor", BR. J. CANCER, (2002), vol. 86, pages 1628 - 1633
    - TOKER, A, "Signalling through protein kinase C", FRONT. BLOSOL., (1998), vol. 3, pages 1134 - 1147
    - WOLF, I, SEGER, R, "The mitogen-activated protein klnase signalling cascade: from bench to bedside", IMAJ., vol. 4, pages 641 - 647
    - SMITH, H,J. ET AL., "Signal transduction pathways Involved In proteolysis-Inducing factor Induced proteasome expression in murine myotubes", BR. J. CANCER, (2003), vol. 89, doi:doi:10.1038/sj.bjc.6601328, pages 1783 - 1788, XP002474063

DOI:   http://dx.doi.org/10.1038/sj.bjc.6601328
    - WHITEHOUSE, A.S. ET AL., "Increased expression of the ubiquilin-proteasome pathway In murine myotubes by proteolysis-Inducing factor (PIF) Is associated with activation of the transcription factor NF-KB, Br", J. CANCER, (2003), vol. 89, pages 1116 - 1122
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.